Cargando…

Correction: Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890649/ https://www.ncbi.nlm.nih.gov/pubmed/29626085 http://dx.doi.org/10.1136/gutjnl-2016-312432corr1

Ejemplares similares

Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
por: Mayerle, Julia, et al.
Publicado: (2018)

Metabolic biomarkers for the differential diagnosis of pancreatic ductal adenocarcinoma vs. chronic pancreatitis
por: Mayerle, Julia, et al.
Publicado: (2014)

Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma
por: Gimotty, Phyllis A., et al.
Publicado: (2022)

Serum biomarkers for the differentiation of autoimmune pancreatitis from pancreatic ductal adenocarcinoma
por: Caba, Octavio, et al.
Publicado: (2023)

Correction to: Analysis of dynamic molecular networks for pancreatic ductal adenocarcinoma progression
por: Pan, Zongfu, et al.
Publicado: (2020)

Correction to: Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal‑venous enhancement phase
por: Reinert, Christian Philipp, et al.
Publicado: (2021)

Markers of Bone Metabolism in Patients With Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma
por: Pezzilli, Raffaele, et al.
Publicado: (2015)

Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modeling
por: Islam, Mohammad Mazharul, et al.
Publicado: (2023)

Correction: Prorenin receptor acts as a potential molecular target for pancreatic ductal adenocarcinoma diagnosis
por: Arundhathi, Arivajiagane, et al.
Publicado: (2019)

Correction: Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma
por: Gruber, Elisabeth S., et al.
Publicado: (2020)

Metabolism remodeling in pancreatic ductal adenocarcinoma
por: Li, Jin-Tao, et al.
Publicado: (2019)

Computed Tomography-Based Radiomics Signature for the Preoperative Differentiation of Pancreatic Adenosquamous Carcinoma From Pancreatic Ductal Adenocarcinoma
por: Ren, Shuai, et al.
Publicado: (2020)

Correction to: Nanotechnology-augmented sonodynamic therapy and associated immune-mediated effects for the treatment of pancreatic ductal adenocarcinoma
por: Hadi, Marym Mohammad, et al.
Publicado: (2023)

The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping
por: Lautizi, Manuela, et al.
Publicado: (2022)

Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma
por: Llop, Esther, et al.
Publicado: (2018)

Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma
por: Kim, Hongbeom, et al.
Publicado: (2020)

Comparative Characterization of Stroma Cells and Ductal Epithelium in Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma
por: Helm, Ole, et al.
Publicado: (2014)

Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma
por: Agrawal, Shefali
Publicado: (2017)

Correction: Impact of TP53 Codon 72 and MDM2 SNP 309 Polymorphisms in Pancreatic Ductal Adenocarcinoma
Publicado: (2015)

Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma
por: Barat, Maxime, et al.
Publicado: (2021)

Ion Channel Signature in Healthy Pancreas and Pancreatic Ductal Adenocarcinoma
por: Schnipper, Julie, et al.
Publicado: (2020)

Correction to: Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer
por: Singh, Kanchan, et al.
Publicado: (2021)

Correction to: Long-term survival after hepatectomy for metachronous liver metastasis of pancreatic ductal adenocarcinoma: a case report
por: Tsutsumi, Chikanori, et al.
Publicado: (2020)

Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma
por: Ormanns, Steffen, et al.
Publicado: (2015)

Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review
por: Wang, Yizhi, et al.
Publicado: (2020)

Potential biomarkers for early detection of pancreatic ductal adenocarcinoma
por: Kriz, D., et al.
Publicado: (2020)

Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers
por: Taherian, Mehran, et al.
Publicado: (2022)

Differentiation of chronic mass-forming pancreatitis from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography
por: Ren, Shuai, et al.
Publicado: (2019)

Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
por: Guo, Shiwei, et al.
Publicado: (2021)

Pancreatic Ductal Adenocarcinoma Associated with Autoimmune Pancreatitis
por: Pezzilli, Raffaele, et al.
Publicado: (2011)

Seven-Signal Proteomic Signature for Detection of Operable Pancreatic Ductal Adenocarcinoma and Their Discrimination from Autoimmune Pancreatitis
por: Yanagisawa, Kiyoshi, et al.
Publicado: (2012)

Correction: MiRNA-615-5p Functions as a Tumor Suppressor in Pancreatic Ductal Adenocarcinoma by Targeting AKT2
por: Sun, Yang, et al.
Publicado: (2015)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)

Models of pancreatic ductal adenocarcinoma
por: Dennaoui, Rayane, et al.
Publicado: (2021)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018)

Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma
por: Chen, Dung-Tsa, et al.
Publicado: (2015)

Establishing and validating an ADCP-related prognostic signature in pancreatic ductal adenocarcinoma
por: Zhang, Deyu, et al.
Publicado: (2022)

Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia
por: Ren, Min, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ffift8asjr1unkapdrtfr54tcv